Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas

Marco Guadagnoli, Fiona Kimberley, Uyen Phan, Katherine Cameron, Paul Vink, Hans Rodermond, Eric Eldering, Arnon Kater, Hans van Eenennaam, Jan Paul Medema

Research output: Contribution to journalArticleAcademicpeer-review


APRIL (A proliferation-inducing ligand) is a TNF family member that binds two TNF receptor family members, TACI and BCMA. It shares these receptors with the closely related TNF family member, B-cell activating factor (BAFF). Contrary to BAFF, APRIL binds heparan sulfate proteoglycans (HSPGs), which regulates cross-linking of APRIL and efficient signaling. APRIL was originally identified as a growth promoter of solid tumors, and more recent evidence defines APRIL also as an important survival factor in several human B-cell malignancies, such as chronic lymphocytic leukemia (CLL). To target APRIL therapeutically, we developed two anti-human APRIL antibodies (hAPRIL.01A and hAPRIL.03A) that block APRIL binding to BCMA and TACI. Their antagonistic properties are unique when compared with a series of commercially available monoclonal anti-human APRIL antibodies as they prevent in vitro proliferation and IgA production of APRIL-reactive B cells. In addition, they effectively impair the CLL-like phenotype of aging APRIL transgenic mice and, more importantly, block APRIL binding to human B-cell lymphomas and prevent the survival effect induced by APRIL. We therefore conclude that these antibodies have potential for further development as therapeutics to target APRIL-dependent survival in B-cell malignancies. (Blood. 2011;117(25):6856-6865)
Original languageEnglish
Pages (from-to)6856-6865
Issue number25
Publication statusPublished - 2011

Cite this